Salvage Surgery for Primary Renal Pelvic Urothelial Carcinoma After Enfortumab Vedotin: A Case of Durable Remission With Nectin-4 Loss.
1/5 보강
[INTRODUCTION] Enfortumab vedotin is a standard therapy for advanced urothelial carcinoma, but its efficacy may be limited by acquired resistance and spatial heterogeneity of Nectin-4 expression.
APA
Wakamiya T, Iwahashi Y, et al. (2026). Salvage Surgery for Primary Renal Pelvic Urothelial Carcinoma After Enfortumab Vedotin: A Case of Durable Remission With Nectin-4 Loss.. IJU case reports, 9(1), e70122. https://doi.org/10.1002/iju5.70122
MLA
Wakamiya T, et al.. "Salvage Surgery for Primary Renal Pelvic Urothelial Carcinoma After Enfortumab Vedotin: A Case of Durable Remission With Nectin-4 Loss.." IJU case reports, vol. 9, no. 1, 2026, pp. e70122.
PMID
41403786 ↗
Abstract 한글 요약
[INTRODUCTION] Enfortumab vedotin is a standard therapy for advanced urothelial carcinoma, but its efficacy may be limited by acquired resistance and spatial heterogeneity of Nectin-4 expression.
[CASE PRESENTATION] We report the case of a 76-year-old woman with cT3N2M0 left renal pelvic urothelial carcinoma that was treated with first-line chemotherapy, followed by pembrolizumab, and subsequently enfortumab vedotin. After 16 cycles of enfortumab vedotin, lymph node metastases remained shrunk, but isolated progression of the primary tumor occurred. Salvage nephroureterectomy was therefore performed, and the patient has remained recurrence-free for one year postoperatively. Immunohistochemistry showed a marked decline in Nectin-4 expression in the resected tumor compared with at the time of the initial biopsy.
[CONCLUSION] This case highlights the potential role of surgery for localized progression during enfortumab vedotin therapy. Nectin-4 reassessment may be considered selectively at decision-changing junctures when results are likely to alter management.
[CASE PRESENTATION] We report the case of a 76-year-old woman with cT3N2M0 left renal pelvic urothelial carcinoma that was treated with first-line chemotherapy, followed by pembrolizumab, and subsequently enfortumab vedotin. After 16 cycles of enfortumab vedotin, lymph node metastases remained shrunk, but isolated progression of the primary tumor occurred. Salvage nephroureterectomy was therefore performed, and the patient has remained recurrence-free for one year postoperatively. Immunohistochemistry showed a marked decline in Nectin-4 expression in the resected tumor compared with at the time of the initial biopsy.
[CONCLUSION] This case highlights the potential role of surgery for localized progression during enfortumab vedotin therapy. Nectin-4 reassessment may be considered selectively at decision-changing junctures when results are likely to alter management.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer Treated With Palbociclib in the POLARIS Study.
- Key Considerations for Targeting in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.
- Overcoming Chemoresistance in Glioblastoma: Mechanisms, Therapeutic Strategies, and Functional Precision Medicine.
- Current Systemic Treatment Options for Advanced Pancreatic Cancer-An Overview Article.
- Balancing safety and efficacy of Bendamustine plus anti CD20 regimens in elderly patients (> 70 y) with follicular lymphoma: a tertiary academic center experience.